Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
How can modelling ensure enough exposure in SAD? – a case study of administration optimization
- At: 2017 FIP Congress in Stockholm (Sweden)
- Type: Poster
- By: CARLERT, Sara (AstraZeneca, Pharmaceutical Sciences, Mölndal, Sweden)
- Co-author(s): Sara Carlert: Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden
Christer Tannergren: Pharmaceutical Technology and Development, AstraZeneca, Mölndal, Sweden
BackgroundsEscalating single dose studies of AZ1 showed limitations in exposure above doses of 200 mg that were likely solubility related, which could potentially jeopardize the future clinical study plan. Time delays for more than a couple of weeks were not permitted, which excluded reformulation of the drug.
AimsThe challenge was to create a new.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019